Log2Lose: Incenting Weight Loss and Dietary Self-monitori... | NCT04770909

ID	Type	Description	Link
A539722	Other Identifier	UW Madison
SMPH/SURGERY	Other Identifier	UW Madison
Protocol Version 1/3/2025	Other Identifier	UW Madison
UG3HL150558-01	U.S. NIH Grant/Contract		View source

Name	Class
Duke University	OTHER
National Heart, Lung, and Blood Institute (NHLBI)	NIH

Label	Type	Description	Intervention Names
Combined	Experimental	Weekly incentives for dietary self-monitoring and weight loss	Behavioral: Incentives for dietary self-monitoring and weight loss
Dietary self-monitoring	Experimental	Weekly incentives for dietary self-monitoring	Behavioral: Incentives for dietary self-monitoring
Weight loss	Experimental	Weekly incentives for weight loss	Behavioral: Incentives for weight loss
Control	No Intervention

Name	Type	Description	Arm Group Labels	Other Names
Incentives for dietary self-monitoring and weight loss	Behavioral	Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss

Measure	Description	Time Frame
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks	Measured on a calibrated, digital scale to the nearest 0.1 kg	26 weeks

Measure	Description	Time Frame
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 52 Weeks	Measured on a calibrated, digital scale to the nearest 0.1 kg	52 weeks
Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 78 Weeks

Measure	Description	Time Frame
Intrinsic Motivation for Weight Loss as Assessed by Modified Treatment Self-Regulation Questionnaire	Association of intrinsic motivation for weight loss with proportion of patients who achieve clinically significant weight loss of at least 5 percent of baseline weight at 26 weeks will be measured with modified version of Treatment Self-Regulation Questionnaire. Intrinsic motivation will be calculated as mean of items 2, 4, 6, 8, 11, 14, 16, 17. Each item can be answered from '1 - not at all true' to '6 - very true'. Lower scores correspond to lower intrinsic motivation for weight loss

Name	Affiliation	Role
Lisa Cadmus-Bertram, PhD	University of Wisconsin, Madison	Principal Investigator
Corrine Voils, PhD	University of Utah Department of Internal Medicine	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Duke University Medical Center		Durham	North Carolina	27705	United States
University of Wisconsin-Madison

PubMed Identifier	Type	Citation	Retractions
41248493	Derived	Shaw RJ, Miller H, Barnes C, Davenport C, Morton-Oswald S, Jackson S, Bean M, Cohen J, Griffin C, Pendergast J, Olsen M, Gierisch J, Voils C. Development, Challenges, and Evolution of the Log2Lose Intervention for Weight Management: Randomized Controlled Digital Health Trial. JMIR Form Res. 2025 Nov 17;9:e70842. doi: 10.2196/70842.
40774423	Derived	Voils CI, Gierisch JM, Pendergast JF, Davenport CA, Olsen MK, Barnes C, Bean M, Cadmus-Bertram L, Colon J, Elwert F, Garza K, Gavin KL, Jackson S, Miller H, Morton-Oswald S, Pabich S, Reed SD, Yancy WS Jr, Shaw RJ. Study protocol for Log2Lose: A randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. Contemp Clin Trials. 2025 Sep;156:108042. doi: 10.1016/j.cct.2025.108042. Epub 2025 Aug 5.

ID	Title	Description
FG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
FG001	Dietary Self-monitoring

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Jul 8, 2025

ID	Title	Description
BG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
BG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
BG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss
BG003	Control	Allocated to no incentives
BG004	Total	Total of all reporting groups

Units	Counts
Participants	BG000175 BG001177 BG002181 BG003173 BG004706

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks

Measured on a calibrated, digital scale to the nearest 0.1 kg

Posted

Count of Participants

Participants

26 weeks

ID	Title	Description
OG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
OG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
OG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss
OG003	Control	Allocated to no incentives

Units	Counts
Participants	OG000160 OG001162 OG002159 OG003

Title

Denominators

Categories

Title	Measurements
	OG00040 OG00143 OG00248 OG003

Secondary

Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 52 Weeks

Measured on a calibrated, digital scale to the nearest 0.1 kg

Posted

Count of Participants

Participants

52 weeks

ID	Title	Description
OG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
OG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
OG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss
OG003	Control	Allocated to no incentives

Secondary

Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 78 Weeks

Measured on a calibrated, digital scale to the nearest 0.1 kg

Posted

Count of Participants

Participants

78 weeks

ID	Title	Description
OG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
OG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
OG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss
OG003	Control	Allocated to no incentives

Secondary

Change in Use of Cardiovascular Medications From Baseline to 78 Weeks for All Participants

Antihypertensive, antilipemic, and type 2 diabetes medications use reported here descriptively as the count of participants who decreased medications, increased medications, or where medications stayed the same.

Data reported for all participants, whether they were taking any prescriptions.

Posted

Count of Participants

Participants

Baseline, 78 weeks

ID	Title	Description
OG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
OG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
OG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss

Secondary

Change in Use of Cardiovascular Medications From Participants Who Took 1 or More Medications From Baseline to 78 Weeks

Antihypertensive, antilipemic, and type 2 diabetes medication use, reported here descriptively as the count of participants with any medications who decreased medications, increased medications, or where medications stayed the same.

Data reported for a subset of participants only, those who took at least 1 medication during the study period.

Posted

Count of Participants

Participants

Baseline, 78 weeks

ID	Title	Description
OG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
OG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
OG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss

Secondary

Diastolic Blood Pressure

Average of two sequential measurements measured on a digital blood pressure monitor. A second reading will be taken one minute after the first. If the difference between the *systolic* measurements is greater than 15mmHg, then a third reading will be taken, one minute after the second reading. Data are model estimated means, baseline values are the same for all groups.

Participants were lost to follow up at subsequent time points.

Posted

Mean

95% Confidence Interval

mmHg

baseline, 26, 52, and 78 weeks

ID	Title	Description
OG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
OG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
OG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss

Secondary

Systolic Blood Pressure

Average of two sequential measurements measured on a digital blood pressure monitor. A second reading will be taken one minute after the first. If the difference between the systolic measurements is greater than 15mmHg, then a third reading will be taken, one minute after the second reading. Data are model estimated means, baseline values are the same for all groups.

Participants were lost to follow up at subsequent time points.

Posted

Mean

95% Confidence Interval

mmHg

26, 52, and 78 weeks

ID	Title	Description
OG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
OG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
OG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss

Other Pre-specified

Intrinsic Motivation for Weight Loss as Assessed by Modified Treatment Self-Regulation Questionnaire

Association of intrinsic motivation for weight loss with proportion of patients who achieve clinically significant weight loss of at least 5 percent of baseline weight at 26 weeks will be measured with modified version of Treatment Self-Regulation Questionnaire. Intrinsic motivation will be calculated as mean of items 2, 4, 6, 8, 11, 14, 16, 17. Each item can be answered from '1 - not at all true' to '6 - very true'. Lower scores correspond to lower intrinsic motivation for weight loss

Not Posted

26 weeks

Participants

Other Pre-specified

Extrinsic Motivation for Weight Loss as Assessed by Modified Treatment Self-Regulation Questionnaire

Association of extrinsic motivation for weight loss with proportion of patients who achieve clinically significant weight loss of at least 5 percent of baseline weight at 26 weeks will be measured with modified version of Treatment Self-Regulation Questionnaire.

Extrinsic motivation will be calculated as mean of items 1, 3, 5, 7, 9, 10, 12, 13, 15, 18. Each item can be answered from '1 - not at all true' to '6 - very true'. Lower scores correspond to lower extrinsic motivation for weight loss

Not Posted

26 weeks

Participants

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Fatigue	Blood and lymphatic system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG0030 affected173 at risk
Cardiac disorder	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Heart Failure	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Myocardial Infarction	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Unspecified Cardiac Block	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Vertigo	Ear and labyrinth disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Fuch's Dystrophy	Eye disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Macular Hole	Eye disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Retinitis Pigmentosa	Eye disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Bowel Obstruction	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Diarrhea	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Diverticulitis	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Gastritis	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Gastrointestinal Issues	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Gallbladder Necrosis	Hepatobiliary disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Bone Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Human Metapneumovirus	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Fall	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Fracture	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Back Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Chest Wall Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Disc Bulge	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Neck Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Torn Meniscus	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Breast Cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0021 affected181 at risk EG003
Mass in Throat	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Uterine Precancerous Cells	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Amnesia	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Parkinson's Disease	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Renal Calculi	Renal and urinary disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Gallbladder Removal	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0012 affected177 at risk EG0020 affected181 at risk EG003
Hernia Repair	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Herniated Disc Repair	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Hysterectomy / Uterine Fibroid Removal	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Inguinal Hernia	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Tendon Repair	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Unspecified Cancer Removal Surgery	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Aneurysm	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Aortic Dissection	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Dyspnea	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Thromboembolic Event	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0012 affected177 at risk EG0020 affected181 at risk EG003
Thromboembolic Event	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Eye Pain	Eye disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Constipation	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Vomiting	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Herniated Disc	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Adrenal Tumor	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Unknown Cancer Origin	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Meniscectomy	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Atrial Fibrillation	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG0031 affected173 at risk
Chest Pain Cardiac	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Dyspnea	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Gastrointestinal Reflux Disease	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Palpitations	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Pericardial Effusion	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Vertigo	Ear and labyrinth disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0012 affected177 at risk EG0020 affected181 at risk EG003
Hashimoto's Thyroiditis	Endocrine disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Thyroid Stimulating Hormone Increased	Endocrine disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Eye Infection	Eye disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Constipation	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0022 affected181 at risk EG003
Gallbladder Sludge	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Gastric Ulcer	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Gastroenteritis	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Gastroesophageal Reflux Disease	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0021 affected181 at risk EG003
Gastrointestinal Pain	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Irritable Bowel Syndrome	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Irritable Bowel Syndrome Attack	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Nausea	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Stomach Pain	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Flu like symptoms	General disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Nausea	General disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Pain	General disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Gallbladder Pain	Hepatobiliary disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Non-Alcoholic Fatty Liver Disease	Hepatobiliary disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Allergic Reaction	Immune system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0021 affected181 at risk EG003
Bacterial Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Bronchial Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Enterocolitis Infectious	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Food Poisoning	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Kidney Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Laryngitis	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Norovirus	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Sinusitis	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Skin Papilloma	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Stomach Virus	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Tooth Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Unspecified Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Unspecified Viral Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Upper Respiratory Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG00013 affected175 at risk EG00116 affected177 at risk EG0029 affected181 at risk EG003
Urinary Tract Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Ankle Sprain	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Arthralgia	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Back Injury	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Bruising	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Burn	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Car Accident Injury	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Fall	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0004 affected175 at risk EG0012 affected177 at risk EG0020 affected181 at risk EG003
Foot Injury	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Fracture	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0012 affected177 at risk EG0023 affected181 at risk EG003
Knee Injury	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Pulled Muscle	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Spinal Fracture	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Torn Meniscus	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Traumatic Amputation	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Hypokalemia	Metabolism and nutrition disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Hypomagnesemia	Metabolism and nutrition disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Low B12	Metabolism and nutrition disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Ankylosing Spondylitis	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0011 affected177 at risk EG0021 affected181 at risk EG003
Back Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0022 affected181 at risk EG003
Bone Spur	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Costochondritis	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Cubital Tunnel Syndrome	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Degenerative Disc Disease	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Fibromyalgia	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Hamstring Sprain / Plantar Fasciitis	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Hip Replacement Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Inguinal Hernia	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Joint Effusion	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Knee Injury	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Lupus	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Muscle Cramp	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Neck Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Polymyalgia Rheumatica	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Rotator Cuff Injury	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Sciatica	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Spondylolisthesis	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Tendonitis	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0021 affected181 at risk EG003
Torn Cartilage	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Torn Meniscus	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0012 affected177 at risk EG0020 affected181 at risk EG003
Melanoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Arterial Injury	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Dizziness	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Excess Cranial Spinal Fluid	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Facial Numbness	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
MS Flare	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Neuralgia	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Paresthesia	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Radial Nerve Neuropathy	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Syncope	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0022 affected181 at risk EG003
Wrist Nerve Pain	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Pregnancy Loss	Pregnancy, puerperium and perinatal conditions	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Depression	Psychiatric disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0011 affected177 at risk EG0021 affected181 at risk EG003
Disordered Eating	Psychiatric disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Chronic Kidney Disease	Renal and urinary disorders	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Renal Calculi	Renal and urinary disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Breast Tissue Swelling	Reproductive system and breast disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Endometriosis	Reproductive system and breast disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Uterine Polyps	Reproductive system and breast disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Allergic Rhinitis	Respiratory, thoracic and mediastinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0021 affected181 at risk EG003
Dyspnea	Respiratory, thoracic and mediastinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Eczema	Skin and subcutaneous tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Fitbit Band Rash	Skin and subcutaneous tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0005 affected175 at risk EG0012 affected177 at risk EG0022 affected181 at risk EG003
Rash Maculo-Papular	Skin and subcutaneous tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Cataract Surgery	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Dental Surgery	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Eyelid Surgery	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Hip Arthroplasty	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Keloid Removal	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Knee Replacement	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Nissen Fundoplication Surgery	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Shoulder Surgery	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Hypertension	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Hypotension	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Orthostatic Hypotension	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Supraventricular Tachycardia	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Thromboembolic Event	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Anemia	Blood and lymphatic system disorders	CTCAE (5.0)	Systematic Assessment	EG0002 affected175 at risk EG0012 affected177 at risk EG0023 affected181 at risk EG003
Monoclonal Gammopathy of Undetermined Significance	Blood and lymphatic system disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Tachycardia	Cardiac disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Conjunctivitis	Eye disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Gastritis	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Toothache	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Small Intestine Bacterial Overgrowth and Intestinal Methanogen Overgrowth	Gastrointestinal disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Edema Limbs	General disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Fatigue	General disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Pain	General disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Lung Infection	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0012 affected177 at risk EG0021 affected181 at risk EG003
Otitis Media	Infections and infestations	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Intraoperative Head and Neck Injury	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Injured Leg	Injury, poisoning and procedural complications	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Hyperglycemia	Metabolism and nutrition disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Hyponatremia	Metabolism and nutrition disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Knee Pain	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
RA Flare	Musculoskeletal and connective tissue disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Headache	Nervous system disorders	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Anxiety	Psychiatric disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Hormonal Changes	Reproductive system and breast disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0021 affected181 at risk EG003
Irregular Menstruation	Reproductive system and breast disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Uterine Fibroids	Reproductive system and breast disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0011 affected177 at risk EG0020 affected181 at risk EG003
Melanoma Removal	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Right Elbow Surgery	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Tooth Extraction	Surgical and medical procedures	CTCAE (5.0)	Systematic Assessment	EG0001 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003
Lymphedema	Vascular disorders	CTCAE (5.0)	Systematic Assessment	EG0000 affected175 at risk EG0010 affected177 at risk EG0020 affected181 at risk EG003

ID	Term
D050177	Overweight
D044343	Overnutrition
D009748	Nutrition Disorders
D009750	Nutritional and Metabolic Diseases
D001835	Body Weight
D012816	Signs and Symptoms
D013568	Pathological Conditions, Signs and Symptoms

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Combined	Weekly incentives for dietary self-monitoring and weight loss Incentives for dietary self-monitoring and weight loss: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss	0	175	9	175	44	175
EG001	Dietary Self-monitoring	Weekly incentives for dietary self-monitoring Incentives for dietary self-monitoring: Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring	1	177	14	177	39	177
EG002	Weight Loss	Weekly incentives for weight loss Incentives for weight loss: Participants can earn up to $300 during the trial for achieving weight loss	1	181	7	181	37	181
EG003	Control	Allocated to no incentives	0	173	8	173	44	173